In the one-year follow-up we observed a significant migraine frequency and allodynia improvement, but no effect on total tenderness score.
In contrast to zoledronic acid, renal dysfunction has not been observed at a significant frequency with denosumab, either when given every 4 weeks or every 6 months for prevention of bone loss.
Compared to the previously reported period (1994 2004), we observed a significant decrease in the frequency of MPGN and significant increases in the frequency of FSGS and, particularly MN - which more than doubled.
In this group we observed a significant reduction in the frequency of headache and neck and shoulder pain, as well as in the frequency of drug consumption, at the end of the trial compared with the 2 months baseline.
We observed a significant reduction in migraine frequency, migraine intensity, use of triptans and pain score.
We only observed a significant increase in the frequency of IgG+ B cells within the CD27hiCD38hi plasmablast population of vaccinated responder HIS mice, as compared to PBS-injected animals (13.2±2.7% and 4.3±1.8% of CD27hiCD38hi B cells, respectively; p = 0.0311).
For all virulent isolates, we observed a significant decrease in the frequency (vir4: t7 = 12.76, p < 0.0001; vir6: t5 = 5.19, p = 0.0035).
Moreover, during these three periods we observed a significant increase in the frequency of ESBL carriers (from 2.1%to7.5%5%; p<0.005).
Moreover, we observed a significant increase in the frequency of combined procedures, while the percentage of delayed fundoplications remained at a relatively stable level.
However, with increasing evolutionary age, we observed a significant increase in the frequency of both partial and chimeric duplicates as well as a concomitant attenuation of duplication spans.
